Cardiovascular Outcomes in Adults Undergoing Cancer Treatment The GMEDICO Cohort Study with 5-Year Cardio-Oncology Follow-Up

What this Trial Is About

The Mediterranean Group of Cardio-Oncology GMEDICO is conducting research to understand the cardiovascular outcomes of patients treated for cancer. This study aims to identify the chances of heart-related problems and find factors that predict cardiovascular events in cancer patients. It also seeks to create a biological collection for testing biomarkers and genetic factors linked to cardiovascular events during cancer treatment. Participants will be monitored for 5 years following a standardized cardio-oncology protocol based on international guidelines and drug-specific information. The study involves regular cardio-oncological follow-ups and management within specialized centers. Additional blood samples will be collected for biobanking. In some cases, a small skin biopsy may be performed to study the hearts response to immunotherapy using advanced cell models. Throughout the study, participants will have cardiac biomarkers measured at regular intervals over 5 years. Researchers will monitor heart health using clinical assessments, biological tests, and imaging methods. Data collected will help develop risk scores for cardiovascular events during cancer treatment. The study is led by Assistance Publique Hopitaux De Marseille and includes careful long-term follow-up and management of participants cardiovascular health.

Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort"